Hosted on MSN2d
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Shares of Capricor Therapeutics CAPR gained 8.4% on Thursday following the completion of the submission of a biologics ...
Targeted Oncology3d
FDA Considers Approval of TLX250-CDx in Kidney Cancer
A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...
Targeted Oncology2d
FDA’s December 2024 Oncology Approvals and Designations
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Managed Healthcare Executive2d
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
Stocktwits on MSN2d
Capricor Therapeutics Stock Surges On BLA Submission for Cell Therapy To Treat Muscular Dystrophy: Retail’s Excited
Shares of Capricor Therapeutics ($CAPR) were up 8.41% up on Thursday after the rare diseases-focused biotech said it ...
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Precigen, Inc. (NASDAQ:PGEN) shares are trading higher on Monday after the company completed the rolling submission for a ...
Capricor Therapeutics completes submission of BLA to FDA for deramiocel
Capricor Therapeutics (CAPR) announced the completion of the submission of its Biologics License Application, BLA, to the U.S. Food and Drug ...
Capricor Completes Submission Of BLA For Deramiocel For Treatment Of Duchenne Muscular Dystrophy
"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...
Contract Pharma2d
Chime Biologics & Mabgeek Complete PPQ for MG-K10
Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sangamo Therapeutics, Inc. ("Sangamo" or the "Company") (NASDAQ: SGMO). Such investors are ...
Benzinga.com6d
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Precigen, Inc. PGEN shares are trading higher on Monday after the company completed the rolling submission for a biologics license application to the FDA for PRGN-2012 (zopapogene imadenovec ...